Biodesix, Inc., a fully integrated molecular diagnostics company advancing the development of products for personalized medicine, today announced that they have received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center. With this certification, VeriStrat®, a serum proteomic test to help physicians guide treatment for patients with non-small cell lung cancer (NSCLC), is now available in all 50 states.
“We are pleased that we can offer the quality and reproducibility of centralized VeriStrat testing and certify that our laboratory performs to the rigorous standards established by CLIA and the New York State Department of Health,” said David Brunel, Chief Executive Officer of Biodesix. “In making VeriStrat broadly available, Biodesix demonstrates our commitment to making personalized medicine a reality for all lung cancer patients.
Biodesix has contributed to the personalization of medicine in lung cancer by introducing VeriStrat, a non-invasive blood test that identifies advanced lung cancer patients who are likely to have good or poor outcomes after treatment with a commonly prescribed drug called erlotinib. VeriStrat testing is performed in Biodesix’ CLIA-accredited laboratory with results returned typically in less than 72 hours. This fast turn-around time allows physicians to make faster treatment decisions.
About Biodesix
Biodesix is a fully integrated molecular diagnostics company advancing the development of products for personalized medicine. Biodesix provides physicians with tools for earlier disease detection, more accurate diagnosis, and better therapeutic guidance. In 2009, Biodesix launched VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer. VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy. The ProTS® platform has broad application and provides the foundation for collaborations with leading researchers as well as partnerships with biotechnology and pharmaceutical companies seeking to develop companion diagnostics and improve the targeting of their therapies. For more information about Biodesix, please visit the Company’s website at www.Biodesix.com.
Media Contacts:
Erik Clausen or Kena Hudson
Chempetitive Group for Biodesix
biodesix@chempetitive.com
(510) 908-0966
